• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical Pediatric Endocrinology >Can Growth Hormone Treatment Improve the Growth Retardation in Children Associated with Steroid Dependent Nephrotic Syndrome
【24h】

Can Growth Hormone Treatment Improve the Growth Retardation in Children Associated with Steroid Dependent Nephrotic Syndrome

机译：生长激素治疗能否改善类固醇依赖型肾病综合征相关儿童的生长发育迟缓

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Impaired growth with decrease in bone mineralization are well-recognized complications of corticosteroid excess, hence children with steroid-dependent nephrotic syndrome (SDNS) who have been on high doses of steroids for prolonged periods often have short stature. Supraphysiological doses of recombinant human growth hormone (rhGH) have been used successfully to treat the short stature in post-renal transplant children who are on steroid treatment. We studied 8 children with long-standing SDNS and growth retardation, in order to determine the efficacy and safety of 1-year rhGH therapy. rhGH was administered at 24 U/m2/week for 1year. The mean prednisolone dose during rhGH treatment was 0.5 mg/kg/day which was not significantly different from the mean dose of 0.4mg/kg/day 1year prior to treatment. The mean (± SD) chronological age was 12.6 (±3.1) years (range 4-18 years). Several patients had significant delay in pubertal stage, with a mean bone age of 9.1 (±2.0) years. The effects of 1-year GH treatment on anthropometric and bone mineral density (BMD) measurements were then evaluated. Mean height velocity of the nephrotic children increased from 3.7 (±1.4) cm/year to 9.4 (±2.1) cm/year (p<0.05). Mean height standard deviation score increased from -1.4 (±1.6) to -0.3 (±1.1) (p<0.05). In the spine, BMD increased from 0.50 g/cm2 to 0.64g/cm2 (p<0.05). Lean body mass increased from 58.1% to 62.6% (p<0.01). There were no significant changes in creatinine clearance, fasting glucose and insulin, and glycosylated hemoglobin levels. In conclusion, 1-year GH therapy was effective in improving growth and bone mineral density in children with SDNS, in the absence of any significant adverse effects.
机译：公认的皮质类固醇过量并发症是生长受损和骨矿化减少的原因，因此长期服用高剂量类固醇的儿童患有类固醇依赖型肾病综合征（SDNS），通常身材矮小。超生理剂量的重组人生长激素（rhGH）已成功用于治疗接受类固醇治疗的肾移植术后儿童的矮小身材。为了确定1年rhGH治疗的有效性和安全性，我们研究了8名长期存在SDNS和生长迟缓的儿童。 rhGH以每周24 U / m2 /的剂量施用1年。 rhGH治疗期间的泼尼松龙平均剂量为0.5 mg / kg /天，与治疗前1年的0.4mg / kg /天的平均剂量无显着差异。时间的平均（±SD）年龄为12.6（±3.1）岁（范围4-18岁）。几例患者的青春期延迟显着，平均骨龄为9.1（±2.0）岁。然后评估了1年GH治疗对人体测量和骨矿物质密度（BMD）测量的影响。肾病儿童的平均身高速度从3.7（±1.4）cm /年增加到9.4（±2.1）cm /年（p <0.05）。平均身高标准偏差评分从-1.4（±1.6）增加到-0.3（±1.1）（p <0.05）。在脊柱中，BMD从0.50 g / cm2增加到0.64g / cm2（p <0.05）。瘦体重从58.1％上升至62.6％（p <0.01）。肌酐清除率，空腹葡萄糖和胰岛素以及糖基化血红蛋白水平无明显变化。总之，在没有任何重大不良影响的情况下，为期1年的GH治疗有效改善了SDNS儿童的生长和骨矿物质密度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号